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I. INTRODUCTION
Patent law in India had its origins in the patent system introduced by Great
1
2
Britain, which ruled India for almost a century. It is well documented that the
 Associate Professor, Public Policy and Management Group, IIM Calcutta, E-mail:
krisunni@rediffmail. com. Author expresses his sincere thanks to Prof. M.S. Mireles, Pacific McGeorge School
of Law, and all academic staff of Max Planck Institute for Intellectual Property and Competition Law-Munich
and Munich Intellectual Property Law Center for their support and guidance in the completion of this write-up.
1. See Rajesh Sagar, Introduction of Exclusive Privileges/Patents in Colonial India: Why and for Whose
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British influence in India had its beginning in 1600 with Queen Elizabeth I’s
chartering of the “Governor and Company of Merchants of London trading into
3
the East Indies,” The English East India Company (“The Company”), which
first came to India in 1608 and laid the foundation for British rule over the next
4
three decades. The British Crown was eventually forced to take full control of
India from the Company in 1858 as a result of a massive revolt against the
5
Company, which is also known as India’s First War of Independence.
The origin of Indian patent law can be traced to 1856, when a law was
enacted in India to grant certain exclusive privileges to inventors for a period of
6
fourteen years. Since the 1856 law did not have the prior sanction of the British
Queen, experts opined that the Legislative Council of India did not have the
7
authority to pass it. The reason given was that since the grant of patents “in
India was a prerogative of the Crown[,]” any patent law passed by the Indian
8
legislature required the prior permission of the Crown or its representative.
Thus, the 1856 Act was repealed when the Indian Legislative Council passed Act
IX of 1857; Act IX was followed by a new law enacted in 1859 that granted
9
inventors the exclusive privilege to make, use, and sell their invention in India.
The purpose of this legislation was to help British patent holders gain control
over the Indian markets, and the law contained major restrictions on the
10
importation of technologies and inventions. As a consequence, importation of
11
technology became highly complex and prohibitively expensive.
Patent law in India continued to be developed and refined over the next
several decades. In 1872, the Patents and Designs Protection Act was enacted,
12
and in 1883 the Protection of Inventions Act was enacted. Finally, in 1888,
13
both these laws were consolidated in the Inventions and Designs Act. The
British enactment of the Indian Patents and Designs Act, 1911, (“1911 Act”)
created a system of patent administration in India under the supervision of a

Benefit, 2 INTELL. PROP. Q. 164, 166 (2007).
2. DENIS JUDD, THE LION AND THE TIGER: THE RISE AND FALL OF THE BRITISH RAJ, 1600-1947, 14-27
(2004).
3. Id. at 6.
4. Id. at 10, 12-17.
5. Id. at 90-91.
6. Sagar, supra note 1, at 173.
7. Id. at 179.
8. Id.
9. Tanuja Garde, India, in INTELLECTUAL PROPERTY IN ASIA: LAW, ECONOMICS, HISTORY AND
POLITICS 55, 57 (Paul Goldstein & Joseph Straus eds., 2009).
10. See id.
11. See id.
12. P. NARAYANAN, PATENT LAW 6 (3d ed. 1998).
13. See History of Indian Patent System, INTELL. PROP. INDIA para. 3, http://www.ipindia.nic.in/ipr/
PatentHistory.htm (last visited Feb. 10, 2012).
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Controller of Patents. The term of patents under the 1911 Act was for sixteen
years after the filing date, and in certain cases it could be extended up to seven
15
additional years. The 1911 Act remained in force—with certain amendments—
and continued to govern the Indian patent system even after India got its
16
independence from Britain in 1947. It was finally repealed by the Patents Act
17
of 1970. All versions of patent law enacted by the British in India allowed for
18
product patents in all fields of technology, including pharmaceuticals.
Even during that period, courts in British India had to deal with a number of
19
patent infringement disputes. When India finally got independence from Britain
in 1947, it had a huge population of 400 million people that represented one-fifth
20
of the world’s population. However, the nation at that time was among the
21
poorest in the world. Slowly, Indian policy makers turned their attention to an
impoverished domestic economy and eradication of the remnants of
22
colonization. While doing so, they observed that even though India had made
23
some progress in industries like steel production, India’s indigenous
pharmaceutical industry had been in very bad shape as a direct result of the 1911
24
Act. The indigenous pharmaceutical industry was highly critical of this Act, as
it prevented them from manufacturing reverse-engineered drugs for which
25
foreign pharmaceuticals held a product patent in India.
Even after India got its independence, its drug industry was tightly controlled
26
by the multinational companies, and most life-saving drugs like insulin,
27
Furthermore, a very
streptomycin, and penicillin were wholly imported.
28
unpopular judgment of the Bombay High Court in 1968 that favored a foreign
patent holder over a local drug manufacturer accelerated the Indian government’s

14. NARAYANAN, supra note 12, at 6.
15. Ved P. Mithal, Patents in India, 30 J. PAT. OFF. SOC’Y 62, 69 (1948).
16. Id. at 65-66; JUDD, supra note 2, at 179.
17. The Patents Act, No. 39 of 1970, INDIA CODE sec. 162(1) (1998).
18. See Srividhya Ragavan, Of the Inequals of the Uruguay Round, 10 MARQ. INTELL. PROP. L. REV.
273, 284 (2006).
19. One such infringement case was Gillette Indus. Ltd. v. Yeshwant Bros., 1937 A.I.R. 40 (Bom.) 347
(India).
20. See DOMINIQUE LAPIERRE & LARRY COLLINS, FREEDOM AT MIDNIGHT 27-28 (1975).
21. See id. at 28.
22. See TIRTHANKAR ROY, THE ECONOMIC HISTORY OF INDIA, 1857-1947, at 180-81 (2000).
23. INDICUS ANALYTICS, INDIAN STEEL INDUSTRY 3-4 (2009), available at http://www.cci.gov.in/
images/media/completed/Indicussteel_20090420151842.pdf.
24. See generally SUDIP CHAUDHURI, THE WTO AND INDIA’S PHARMACEUTICALS INDUSTRY: PATENT
PROTECTION, TRIPS, AND DEVELOPING COUNTRIES 128 (2005).
25. Id. at 129.
26. Ragavan, supra note 18, at 280.
27. See PLANNING COMM’N, GOV’T OF INDIA, 1ST FIVE YEAR PLAN ch. 32 paras. 94-99 (1952),
available at http://planningcommission.nic.in/plans/planrel/fiveyr/default.html.
28. See generally Farbwerke Hoechst & Bruning Corp. v. Unichem Lab., 1969 A.I.R. 56 (Bom.) 255
(India).
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resolve to implement drastic changes in the patent law that would enable Indian
29
companies to make drugs at much cheaper prices.
The Bombay High Court judgment mentioned above dealt with a patent
infringement suit filed by the owners of an Indian patent for the manufacture of
new sulphonyl-urea compounds, salts of those compounds, and of anti-diabetic
30
medications containing those compounds. One of the chemical compounds
covered by the patent was Tolbutamide, and “since 1957 the plaintiffs had been
marketing [it] as an anti-diabetic drug in India and all over the world under the
31
trademark ‘Rastinon.’”
The main argument raised by the plaintiffs was that the defendant had
wrongfully infringed upon their patent by manufacturing, preparing, and selling
32
Tolbutamide by the use of the invention disclosed in the plaintiffs’ patent. The
first defendant admitted that it had manufactured Tolbutamide, but claimed that it
“had been manufactured by the application of the processes mentioned in another
33
patent,” held by the Haffkine Institute of Bombay, the second defendant. The
first defendant also raised a counter-claim to revoke the patent “on the grounds of
insufficiency of description, lack of novelty, want of inventive step and lack of
34
utility.” The Court held the patent to be valid and restrained the first defendant
35
from further infringement upon the plaintiffs’ patent.
It should be noted that the process of drafting a patent law in-tune with
36
India’s needs began immediately after independence. Initially a committee
under the chairmanship of Justice Tek Chand was appointed by the Indian
government in 1949 to review the patent laws in India with the purpose of
37
ensuring that the patent system was more conducive to national interests. The
committee submitted its interim report in 1949, providing recommendations for
38
prevention of misuse or abuse of patent rights in India. The Tek Chand Report
led to an important amendment to the existing patent law in 1950 that dealt with
39
the working of inventions and compulsory licenses/revocation. The amendment
also included provisions dealing with endorsement of patents “with the words
‘license of right’ on an application by the Government,” enabling the Controller
40
to issue such licenses.

29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
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See Ragavan, supra note 18, at 87-88.
Farbwerke Hoechst & Bruning Corp., 1969 A.I.R. 56, at para. 1.
Id.
Id.
Id.
Id. at para. 2.
Id. at para. 21.
See History of Indian Patent System, supra note 13, at paras. 6-7.
Id. at para. 5.
Id. at para. 6.
Id. at para. 7.
Id. This included provisions dealing with compulsory license on patents dealing with food and
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Though the Tek Chand Report was important, it was the second report
commissioned by the Indian government, under the chairmanship of Justice N.
Rajagopala Ayyangar, which set the tone and tenor of India’s current patent
41
law. According to some leading scholars, the Ayyangar Report formed the
42
backbone of the Indian patent system by recommending drastic modifications.
The Ayyangar Report found that multinational companies “held about 80-90% of
43
Indian patents, but practiced less than 10% of those patents in India.”
The Ayyangar Report recommended revolutionary changes to India’s
existing patent laws to accommodate the country’s inexperienced industrial
44
sectors and to encourage and reward inventors. The recommendations primarily
focused on:
(i) classification of the types of inventions for which patent protection
should be available;
(ii) provisions intended either to prohibit the granting of Indian patents
to foreign entities or to require working of such patents in India; and
(iii) provisions intended to resist international pressures on India to join
international intellectual property conventions such as the Paris
45
Convention, which demanded national treatment.
The Ayyangar Report noted that the precise provisions of any patent law
should be designed with special reference to the economic conditions of the
country, the level of its science and technological advances, and its future
46
needs. In spite of all the perceived shortcomings of the Indian patent system,
the Ayyangar Report wanted to continue with the system, as it was one of the
47
most desirable ways of encouraging and rewarding innovators.
The Ayyangar Report led to the introduction of the Patents Bill, 1965, in the
48
Indian parliament.
After deliberations including scrutiny by the Joint
Parliamentary Committee, the Patents Act, 1970, was passed by the Indian

medicines, insecticide, germicide or fungicide and a process for producing substance or any invention relating
to surgical or curative devices. Id.
41. See generally N. RAJAGOPALA AYYANGAR, REPORT ON THE REVISION OF THE PATENTS LAW
(1959).
42. Ragavan, supra note 18, at 281; NARAYANAN, supra note 12, at 5.
43. Linda L. Lee, Trials and TRIPS-ulations: Indian Patent Law and Novartis AG v. Union of India, 23
BERKELEY TECH. L.J. 281, 290 (2008).
44. See generally AYYANGAR, supra note 41, at paras. 18-42.
45. Id.
46. Id. at para. 44.
47. Id. at para. 43.
48. History of Indian Patent System, supra note 13, at para. 8.
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49

parliament. The law contained an express prohibition dealing with patentability
50
of pharmaceutical products; however, it permitted patents on processes for
making pharmaceutical compounds, even though the duration of those patents
51
was shorter than other types of patents.
The Patents Act, 1970, along with the National Drug Policy announced in
1978, acted as an incentive for public sector units like Hindustan Antibiotics Ltd.
and Indian Drugs and Pharmaceuticals Ltd., along with many private sector units,
52
to make essential drugs at affordable prices. As financial resources were scarce
at that time, the pharmaceutical industry emphasized generic drug production,
and virtually no investment was made on original research to develop new
53
molecules.
By enacting the 1970 law, the Indian government made a conscious decision
to kick-start the lagging Indian economy by supporting domestic drug
54
manufacturing. During the next three decades, India emerged as a globally
55
recognized producer of low-price generic drugs. As recently as 2005, India was
ranked number one in the world with respect to generic drug production, and it is
a leading exporter of medicines to developing countries, including a large
56
percentage of medicines used combat AIDS.
India’s pharmaceutical patent regime began to change slowly with its
57
accession to the World Trade Organization (“WTO”) in 1995. The agreements
that accompany membership in the WTO cover goods, services, and intellectual
58
property rights (“IPRs”). One of the most important agreements within the

49. Id. The 1970 law repealed and substituted the 1911 Act so far as the patents law was concerned.
However, the 1911 Act continued to be applicable to designs. The provisions of the 1970 Act became effective
on April 20, 1972. Id.
50. The Patents Act, No. 39 of 1970, INDIA CODE sec. 5(a)-(b) (1998). As per the said provisions, a
patent cannot be granted for “substances intended for use, or capable of being used, as food or as medicine or
drug, or . . . relating to substances prepared or produced by chemical processes (including alloys, optical glass,
semi-conductors and inter-metallic compounds).” Id.
51. Id. at sec. 53 (“[I]n respect of an invention claiming the method or process of manufacture of a
substance, where the substance is intended for use, or is capable of being used, as food or as a medicine or drug,
be five years from the date of sealing of the patent, or seven years from the date of the patent whichever period
is shorter.”).
52. Santanu Mukherjee, The Journey of Indian Patent Law Towards TRIPs Compliance, 35 INT’L REV.
INTELL. PROP. & COMPETITION L. 125, 128-29 (2004).
53. Id.
54. Janice M. Mueller, The Tiger Awakens: The Tumultuous Transformation of India’s Patent System
and the Rise of Indian Pharmaceutical Innovation, 68 U. PITT. L. REV. 491, 514 (2007).
55. See id. at 514-16.
56. See MEDÉCINS SANS FRONTIÈRES, UNTANGLING THE WEB OF PRICE REDUCTIONS: A PRICING GUIDE
FOR THE PURCHASE OF ARVS FOR DEVELOPING COUNTRIES 3 (8th ed. 2005), available at http://www.doctors
withoutborders.org/publications/reports/2005/untanglingthewebv8.pdf.
57. Member Information: India and the WTO, WORLD TRADE ORG., http://www.wto.org/english/
thewto_e/countries_e/india_e.htm (last visited Feb. 2, 2012).
58. Details about WTO agreements are available at Understanding the WTO: The Agreements,
Overview: A National Guide, WORLD TRADE ORG., http://www.wto.org/english/thewto_e/whatis_e/tif_e/
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WTO is the Trade-Related Aspects of Intellectual Property (“TRIPS”)
Agreement, which mandates that all WTO members adopt and enforce certain
59
60
minimum standards of IPR protection. In 1986, when the negotiations for
setting up the WTO began, India and other developing countries—including
Brazil and Argentina—strongly opposed it on the premise that protection of IPRs
fell within the mandate of the World Intellectual Property Organization
61
(“WIPO”). By 1989, other developing countries changed their stance because
of various coercive measures taken by the United States, and India was left alone
62
in its opposition. Thus, India—faced with the unviable alternative of remaining
completely outside the WTO system—was forced to sign the TRIPS Agreement
63
and join the WTO in 1995. However, in the process, India also managed to
extract crucial flexibilities with respect to patent laws that had the result of
64
restricting the effects of the changes originally mandated by TRIPS.
It is a well-accepted fact that India’s objections to the TRIPS Agreement
benefited many developing countries, since all of them were provided transition
65
periods of several years by WTO to make their laws fully TRIPS compatible.
Even though India was not required to comply with the product patent
requirements of TRIPS until 2005, it was mandated to create a mailbox for the
filing of patent applications that would be examined when the 2005 changes
66
came into effect.
India’s WTO entry, although a very important step, cannot be attributed as
the sole reason for changing its patent/IPR laws. It also had something to do with
the drastic changes in economic policy that started in the 1990’s. Right from
1947, when India became independent, it adopted a closed-economy model

agrm1_e.htm (last visited Feb. 26, 2012).
59. A brief summary of the TRIPS Agreement is available at Agreement on Trade Related Aspects of
Intellectual Property Rights, Including Trade in Counterfeit Goods, WORLD TRADE ORG., http://www.
wto.org/english/docs_e/legal_e/ursum_e.htm#nAgreement (last visited Feb. 26, 2012).
60. The round of negotiations which led to the formation of the WTO is popularly known as The
Uruguay Round. It took more than seven years to complete the process and is believed to be the largest trade
negotiation in history. The Uruguay Round, WORLD TRADE ORG., http://www.wto.org/english/thewto_e/
whatis_e/tif_e/fact5_e.htm (last visited Feb. 26, 2012).
61. See generally Peter Drahos, Developing Countries and International Intellectual Property StandardSetting 9 (Comm’n on Intellectual Prop. Rights, Study Paper 8, 2002), available at http://www.
iprcommission.org/papers/pdfs/study_papers/sp8_drahos_study.pdf.
62. See Robert C. Bird & Daniel R. Cahoy, The Emerging BRIC Economies: Lessons from Intellectual
Property Negotiation and Enforcement, 5 NW. J. TECH. & INTELL. PROP. 400, 403-04 (2007).
63. See Amy Kapczynski, Harmonization and Its Discontents: A Case Study of TRIPS Implementation in
India’s Pharmaceutical Sector, 97 CAL. L. REV. 1571, 1579 (2009).
64. Id. at 1581.
65. George K. Foster, Opposing Forces in a Revolution in International Patent Protection: The U.S. and
India in the Uruguay Round and Its Aftermath, 3 UCLA J. INT’L L. & FOREIGN AFF. 283, 311-12 (1998).
66. Agreement on Trade-Related Aspects of Intellectual Property Rights art. 70.8(a), Apr. 15, 1994,
Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, available at
http://www.wto.org/english/docs_e/legal_e/27-trips.pdf.
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characterized by extensive regulation and state intervention that resulted in
67
decades of low growth rates. This continued for more than four decades until
1991, when India was forced to take some concrete steps towards economic
68
liberalization as a result of the balance of payment crisis.
As part of the
liberalization package, India had to devalue its currency, remove various import
controls, slash customs duty rates, significantly liberalize industrial licensing
norms, and open up the capital markets so that foreign investment could be
69
attracted in numerous sectors.
Thus, it is possible that when India became a member of the WTO in 1995,
the economic liberalization policies it implemented four years before played
some role in diluting India’s stiff opposition to including IPRs within the ambit
of the WTO. After the economic liberalization, India was in a much better
position to align its policy interests with the fundamental philosophy of the
WTO. Post-1991, free trade and greater engagement with the global economy
began to be accepted among its policy makers as something that was not
70
undesirable.
II. PATENT AMENDMENTS POST 1995
TRIPS accelerated the transformation of India’s patent laws in a multi71
phased manner that corresponded to three amendments to the Patents Act, 1970.
Initially a mailbox facility was established, which allowed applicants to file
72
Applicants were to be given
pharmaceutical product patent applications.
exclusive marketing rights (“EMRs”), subject to certain conditions, to market the
73
product for a period up to five years from the date of grant. The second
74
amendment to the 1970 law was made in 2002. This amendment brought it into
conformity with TRIPS on many issues, as it provided for a twenty year patent
75
76
term, reversal of the burden of proof for process patent infringement, and
77
modifications to compulsory licensing requirements. By virtue of the third

67. TUSHAR PODDAR & EVA YI, GOLDMAN SACHS, GLOBAL ECONOMICS PAPER NO. 152: INDIA’S
RISING GROWTH POTENTIAL 4 (2007), available at http://www.usindiafriendship.net/viewpoints1/Indias_
Rising_Growth_Potential.pdf.
68. STEPHEN P. COHEN, INDIA: EMERGING POWER 101 (2001).
69. Id.; Mueller, supra note 54, at 517.
70. COHEN, supra note 68, at 101.
71. Mueller, supra note 54, at 519.
72. Id.
73. The Patents (Amendment) Act, 1999, No. 17 sec. 24(B)(1)(a)-(b), Acts of Parliament, 1999 (India),
available at http://ipindia.nic.in/ipr/patent/patact_99.PDF.
74. The Patents (Amendment) Act, 2002, No. 38, Acts of Parliament, 2002 (India), available at
http://www.ipindia.nic.in/ipr/patent/patentg.pdf.
75. Id. at sec. 27(a).
76. Id. at sec. 43.
77. Id. at sec. 39 (substituting ch. XVI, paras. 84-92).
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amendment in 2005, the 1970 law offered patent protection to pharmaceutical
79
products, and in the process became substantially compliant with TRIPS.
III. PATENTS AMENDMENT ACT 1999
Even though India was given exemptions from implementing
pharmaceutical/agrochemical product patents until 2005, it was mandated to set
up a mailbox facility for such product patent applications filed during the TRIPS
80
transition period and to assign each application a filing date. Another obligation
under TRIPS was the provision dealing with the grant of EMRs for mailbox
81
applications that met specified conditions during the transition period. India
initially tried to implement the mailbox facility and grant EMRs by way of a
82
presidential order. For various reasons the Indian parliament failed to pass the
83
law dealing with mailbox facility and EMRs. This prompted the United States
to utilize the WTO’s dispute resolution mechanism to address India’s failure to
84
enact the mailbox and EMR regime into a law. The WTO’s Appellate Body
held in December 1997 that India’s failure to make timely amendments to its
patent laws had resulted in its non-fulfillment of obligations covered by Article
70.8(a) of the TRIPS Agreement, which mandated that India establish “a means”
that adequately preserved novelty and priority of pharmaceutical product patent
85
applications. Finally, in March 1999, the amendment was passed by the Indian
parliament; India formally implemented the mailbox procedure for
pharmaceutical product patent applications and gave it retroactive application
86
from January 1, 1995.

78. See generally The Patents (Amendment) Act, 2005, No. 15, Acts of Parliament, 2005 (India),
available at http://ipindia.nic.in/ipr/patent/patent_2005.pdf.
79. D.K. Nauriyal, TRIPS-Compliant New Patents Act and Indian Pharmaceutical Sector: Directions in
Strategy and R & D, INDIAN J. ECON. & BUS. 189 (2006).
80. Mueller, supra note 54, at 519.
81. Id. at 520.
82. The Patents (Amendment) Ordinance, 1994, No. 13, Acts of Parliament, 1994 (India), available at
http://www.wipo.int/clea/docs_new/pdf/en/in/in001en.pdf. Presidential authority for the promulgation of an
ordinance is derived from Article 123(1) of the Indian Constitution. INDIA CONST. art. 123(1). Ordinances are
promulgated as a stop-gap measure to deal with urgent situations when the Indian Parliament is not in session
and the President of India is satisfied that circumstances exist which render it necessary for him/her to take
urgent action. Id. Ordinances lapse six weeks after the meeting of the Parliament. Id. at art. 123(2)(a). The
Patents (Amendment) Ordinance lapsed six weeks after the meeting of the Parliament.
83. Mueller, supra note 54, at 520.
84. Ruth L. Okediji, Public Welfare and the Role of the WTO: Reconsidering the TRIPS Agreement, 17
EMORY INT’L L. REV. 819, 890-93 (2003).
85. Appellate Body Report, India—Patent Protection for Pharmaceutical and Agricultural Chemical
Products, WT/DS50/AB/R (Dec. 4, 1997), available at http://www.wto.org/english/tratop_e/dispu_e/cases_
e/ds50_e.htm.
86. Mukherjee, supra note 52; The Patents (Amendment) Act, 1999, No. 17 sec. 24(B)(1)(a)-(b), Acts of
Parliament, 1999 (India), available at http://ipindia.nic.in/ipr/patent/patact_99.PDF.
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Mailbox applications were deposited in a “black box,” and they were not
87
taken out for examination until March 2005. During India’s ten-year TRIPS
transition period, 8926 mailbox applications were filed in the four branches of
88
the Indian Patent Office. The framework for filing mailbox applications, in
order to comply with the TRIPS transition requirements, ended for India on
89
December 31, 2004. This means that the provisions dealing with mailbox
applications/ EMRs became obsolete in 2005 and they have been repealed by
90
way of the 2005 amendment.
Few applicants who filed mailbox applications during the TRIPS transition
91
period took the additional step of seeking EMRs for their inventions. The grant
of an EMR would have conferred the exclusive right to sell or distribute the
invention in India for a period of five years from the date of the grant until either
a patent was granted, or the application was finally rejected, whichever was
92
earlier. An EMR was granted only for those inventions claimed in mailbox
applications that further satisfied the following requirements:
(a) an examination by the Indian Patent Office had established that the
invention did not fall within any of the categories of subject matter
considered as non-patentable inventions like business methods,
frivolous inventions, mere admixture, or within the scope of the
93
prohibition on patenting inventions relating to atomic energy;
(b) the mailbox/EMR applicant had filed a patent application for the
same invention, claiming the “identical article or substance” in a
94
“convention country” on or after January 1, 1995;
(c) the mailbox/EMR applicant had been granted a patent by the
convention country on or after the date it filed its mailbox
95
application in India;

87. Mueller, supra note 54, at 521-22.
88. Id. at 522, n.175.
89. Id. at 522.
90. Mukherjee, supra note 52, at 7 (Patents Amendment 2005 which states that Chapter IVA of the 1970
Law shall be omitted).
91. Mueller, supra note 54, at 525.
92. Mukherjee, supra note 52; The Patents (Amendment) Act, 1999, No. 17 sec. 24(B)(1), Acts of
Parliament, 1999 (India), available at http://ipindia.nic.in/ipr/patent/patact_99.PDF; The Patents (Amendment)
Act, 2002, No. 38 sec. 4(k), Acts of Parliament, 2002 (India), available at http://www.ipindia.nic.in/
ipr/patent/patentg.pdf.
93. The Patents (Amendment) Act, 2002, No. 38 sec. 24A(2), Acts of Parliament, 2002 (India) (nonpatentable inventions are covered under Section 3 and inventions relating to atomic energy are covered in
Section 4).
94. Id. at sec. 24B(1)(a).
95. Id.
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(d) the convention country had issued “approval to sell or distribute the
article or substance” in the convention country, “on the basis of
appropriate tests conducted” in the convention country on or after
96
January 1, 1995;
(e) an authority on behalf of the Indian government had given approval
97
to sell or distribute the article in India.
IV. THE PATENTS (AMENDMENT) ACT, 2002
Although the 2002 amendment brought into force numerous changes, the
98
most significant was the extension of the patent term to twenty years. The 2002
Act amended the 1970 law to ensure that the terms of all patents granted in India
99
Before this
would expire twenty years after their application filing date.
amendment, Indian process patents granted in the field of pharmaceuticals lasted
for only five years from sealing, or seven years from the date of the patent,
whichever was less, while the term of all other types of patents was fourteen
100
years from the date of the patent.
101
The 2002 amendment cemented India’s accession to the Paris Convention
102
and Patent Co-operation Treaty. The two treaties are administered by WIPO,
103
and India signed both in 1998.
This meant that India had to make its laws
consistent with the Paris Convention’s national treatment principle—which
104
prohibits discriminatory treatment of foreign applicants —as well as its right of
priority—which permits foreigners who have previously filed a patent
application in their home countries a twelve-month priority period within which
they can file an application for the same invention in India, while still retaining
105
the benefit of their earlier home country filing date.

96. Id. at sec. 24B(1)(b).
97. See generally id. at sec. 24B.
98. The Patents (Amendment) Act, 2002, No. 38 sec. 2, Acts of Parliament, 2002 (India), available at
http://www.ipindia.nic.in/ipr/patent/patentg.pdf (amending section 53). This was mandated by Article 33 of the
TRIPS Agreement.
99. Id. (amending Section 53(1)(a)).
100. Id.; The Patents Act, No. 39 of 1970, INDIA CODE sec. 53(1) (1998).
101. See generally Paris Convention for the Protection of Industrial Property, Mar. 20, 1883, 21 U.S.T.
1583, 828 U.N.T.S. 305, available at http://www.wipo.int/treaties/en/ip/paris/trtdocs_wo020.html.
102. Mueller, supra note 54, at 527; The Patent Co-operation Treaty, June 19, 1970, 28 U.S.T. 7645,
1160 U.N.T.S. 231, available at http://www.wipo.int/pct/en/texts/articles/atoc.htm.
103. Elijah Cocks, India Joins the Patent Cooperation Treaty, 1998 B.C. INTELL. PROP. & TECH. F.
111701, available at http://www.bc.edu/bc_org/avp/law/st_org/iptf/headlines/content/1998111701.html (last
visited Feb. 23, 2012); Mueller, supra note 54, at 527.
104. Paris Convention for the Protection of Industrial Property, supra note 101, at art. 2.
105. Id. at art. 4(C)(1).
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The 2002 amendment brought into force other changes aimed at bringing
India’s patents law in tune with the TRIPS Agreement, including new definitions
106
of invention and inventive step, and new exclusions from patentable subject
107
108
109
The
matter like business methods, algorithms, and traditional knowledge.
amendment also reversed the burden of proof provision involving cases of
110
process patent infringement
and streamlined the compulsory licensing
111
The 2002 amendment also paved the way for patentability of
framework.
112
microorganisms.
The 2002 amendment provides three grounds for seeking a compulsory
patent license. First, the law provides the broadest grounds for seeking a
113
compulsory patent license in the case of non-working of patented inventions.
Such a license can be sought only three years after the sealing of the concerned
114
patent. Second, there is another provision for grant of compulsory licenses on
notification of the Indian government in circumstances of national emergency or
115
extreme urgency like the breakout of epidemics. Third, there is a provision for
compulsory licenses in the case of certain patents that are essential to the
116
efficient working of other patented inventions. The 2002 amendment abolished
117
the concept of Licenses of Right.
Under this concept, process patents
pertaining to medicines and food “were automatically deemed to be endorsed
with the words ‘licenses of right,’” which would make them available for
118
compulsory licensing by all applicants three years after the patent grant.

106. The Patents (Amendment) Act, 2002, No. 38 sec. 3, Acts of Parliament, 2002 (India), available at
http://www.ipindia.nic.in/ipr/patent/patentg.pdf (amending section 2(1), (j) and adding sections 2(1), (ja)).
107. Id. at sec. 4 (adding section 3(k)).
108. Id.
109. Id. at sec. 4 (adding section 3(p)).
110. Id. at sec. 43 (adding section 104A).
111. Id. at sec. 39 (substituting the previous provisions with a whole new chapter dealing with
Compulsory Licensing, Chapter XVI).
112. Id. at sec. 4 (adding section 3(j) dealing with plant varieties. India drafted a new law called
Protection of Plant Varieties and Farmer’s Rights 2001 to give effective protection to plant varieties.).
113. Id. at sec. 84(1).
114. Id. at sec. 84.
115. Id. at sec. 92.
116. Id. at sec. 91.
117. The Patents (Amendment) Act, 1999, No. 17 sec. 87, Acts of Parliament, 1999 (India), available at
http://ipindia.nic.in/ipr/patent/patact_99.PDF; see The Patents (Amendment) Act, 2002, No. 38, Acts of
Parliament, 2002 (India), available at http://www.ipindia.nic.in/ipr/patent/patentg.pdf (abolishing section 87 of
the Patents (Amendment) Act of 1999); see also M. B. RAO & MANJULA GURU, PATENT LAW IN INDIA 251
(2010).
118. Mueller, supra note 54, at 600.

334

[12] UNNI 4-19-12.DOC (DO NOT DELETE)

9/10/2012 3:01 PM

Global Business & Development Law Journal / Vol. 25
V. THE PATENTS (AMENDMENT) ACT, 2005
The last step in India’s implementation of the changes required to make its
119
patent law TRIPS compliant happened by way of the 2005 amendment.
Through this amendment, Indian law, for the first time since 1970, allowed
patent protection to substances capable of being used as pharmaceuticals, food,
120
and agro-chemicals.
The 2005 amendment was preceded by a presidential
121
ordinance in 2004. After its promulgation, there were intense debates about the
scope of various provisions, but the Indian Parliament enacted the 2005
122
amendment after making changes in the ordinance.
The 2005 amendments contain many controversial features that have caused
123
They include elaborate provisions concerning what is and is
many disputes.
124
not considered patentable subject matter, a new definition of the “inventive
125
step” criterion of patentability, procedures governing both pre- and post-grant
126
127
opposition, and a more liberal framework for compulsory licensing.
VI. FLEXIBILITIES BUILT INTO THE INDIAN PATENT LAW
This section will try to cover the important features of India’s current patent
law, which is armed with several flexibilities that the TRIPS Agreement provides
to its member states.
A. Section 3(d) of the Patents Act
This is a newly introduced provision in the patent law, and has led to some
128
famous patent disputes between multinational and Indian companies. Section
3(d) states that

119. Id. at 529.
120. The Patents (Amendment) Act, 2005, No. 15 sec. 3, Acts of Parliament, 2005 (India), available at
http://ipindia.nic.in/ipr/patent/patent_2005.pdf (deleting section 5 of the 1970 Law which prohibited product
patents on the said substances).
121. The Patents (Amendment) Ordinance, 2004, No. 7, Acts of Parliament, 2004 (India), available at
http://lawmin.nic.in/Patents%20Amendment%20Ordinance%202004.pdf.
122. Mueller, supra note 54, at 529-30.
123. Id.
124. These changes inserted by substituting Section 3(d) of the 1970 Law with a new definition. The
Patents (Amendment) Act, 2005, No. 15 sec. 2, Acts of Parliament, 2005 (India), available at http://ipindia.
nic.in/ipr/patent/patent_2005.pdf.
125. These changes inserted by substituting section 2 (ja) of the 1970 Law with a new definition. Id.
126. These changes inserted by substituting Sections 25 and 26 with a new definition. Id. at sec. 23.
127. These changes inserted by adding Section 92A to the 1970 Law. Id. at sec. 55.
128. Raheel Rashad Daureeawo, The Controversy of Section 3(D) of The Indian Patent Act, LEGAL
SERVICE INDIA (Nov. 22, 2009), http://www.legalserviceindia.com/article/l400-Controversy-of-Section-3(D)of-The-Indian-Patent-Act.html.
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the mere discovery of a new form of a known substance which does not
result in the enhancement of the known efficacy of that substance or the
mere discovery of any new property or new use for a known substance or
of the mere use of a known process, machine or apparatus cannot be
129
considered as an invention.
It further clarifies that “salts, esters, ethers, polymorphs, metabolites, pure
form, particle size, isomers, mixtures of isomers, complexes, combinations and
other derivatives of known substance shall be considered to be the same
130
substance, unless they differ significantly in properties with regard to efficacy.”
This amendment’s objective is to prevent the grant of frivolous patents on
131
substances that are only trivial modifications of existing inventions. Within the
pharmaceutical industry, it is very common for companies to try to extend patent
protection by obtaining separate patents on multiple attributes of a single
132
product.
Even though Section 3(d) might have been the first provision
targeting trivial modifications of pharmaceutical inventions to be codified
anywhere in the world, many countries like the United States have devised ways
133
to deal with such patents.
U.S. courts rely upon the doctrine of inherent
anticipation to deal with such patents, and this was demonstrated by the U.S.
Court of Appeals for the Federal Circuit (“CAFC”), which invalidated a patent
on the metabolite of the antihistamine drug Loratadine because the metabolite
“necessarily and inevitably” formed from ingestion of Loratadine under normal
134
conditions.
The United Kingdom also follows a similar approach while dealing with
pharmaceutical patents involving trivial modifications. The England and Wales
Court of Appeal, while dealing with the case of Les Laboratoires Servier v.
Apotex Inc., invalidated a patent on a particular crystalline form of the tert135
butylamine salt of Perindopil. The Court also made the following observations:
It is the sort of patent which can give the patent system a bad name. I am
not sure that much could have been done about this at the examination
stage. There are other sorts of cases where the Patent Office examination
is seen to be too lenient. But this is not one of them. For simply
comparing the cited prior art (‘341) with the patent would not reveal lack

129. The Patents (Amendment) Act, 2005, No. 15 sec. 2, Acts of Parliament, 2005 (India), available at
http://ipindia.nic.in/ipr/patent/patent_2005.pdf.
130. Id.
131. See id. at sec. 3(d); Daureeawo, supra note 128.
132. Carlos M. Correa, Public Health and Patent Legislation in Developing Countries, 3 TUL. J. TECH.
& INTELL. PROP. 1, 30 (2001).
133. Daureeawo, supra note 128.
134. Schering Corp. v. Geneva Pharm., Inc., 339 F.3d 1373 (Fed. Cir. 2003).
135. Full text available at Les Laboratories Servier v. Apotex, Inc., [2008] EWCA (Civ) 445, (Eng.).
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of novelty and probably not obviousness. You need the technical input
of experts both in the kind of chemistry involved and in powder X-ray
diffraction and some experimental evidence in order to see just how
specious the application for the patent was. The only solution to this
type of undesirable patent is a rapid and efficient method for obtaining its
revocation. Then it can be got rid of before it does too much harm to the
136
public interest.
Scholars point out that Section 3(d) is a “bold legislative move” that has the
potential to curb the illegitimate “evergreening” of patents and may compel other
137
countries to imitate India’s example in attempting to curb such practices.
B. Application of Section 3(d)—Novartis Case
In May 2006, Novartis petitioned before the Madras High Court, contending
that the Patent Controller erroneously rejected its patent application for the drug
beta crystalline form of imantinib mesylate under Section 3(d) of the Patents
138
139
Act.
Novartis also argued that the provision violated Article 14 of the
Constitution of India because the wide breadth of discretion given to the patent
140
controller could lead to discriminatory results. The case was split up between
the Madras High Court and the Intellectual Property Appellate Board
141
(“IPAB”).
The challenges on TRIPS compliance and the constitutionality of
Section 3(d) were heard by the Madras High Court, which issued a judgment
142
against Novartis. The issue dealing with patentability was heard by the IPAB,
143
which also ruled against Novartis.
The High Court had to examine three issues. The first was whether Indian
courts had jurisdiction to review Section 3(d)’s consistency with Article 27 of
TRIPS, and to grant declaratory relief if the section was not consistent with

136. Id. at para. 9.
137. Rajarshi Sen & Adarsh Ramanujan, Pruning the Evergreen Tree or Tripping up Over TRIPS?—
Section 3(d) of the Indian Patents Act, 1970, 41 INT'L REV. INTELL. PROP. & COMPETITION L. 170, 186 (2010).
138. Novartis AG v. Union of India, 2007 A.I.R. 24759 (Madras H.C.) para. 1 (2007); The Patents
(Amendment) Act, 2005, No. 15 sec. 3(d), Acts of Parliament, 2005 (India), available at http://ipindia.nic.in/
ipr/patent/patent_2005.pdf (excluding derivatives of known substances from being issued to a patent).
139. Article 14 of the Indian Constitution deals with equality before law; it states that the State shall not
deny to any person equality before the law or the equal protection of the laws within the territory of India. INDIA
CONST. art 14.
140. Novartis AG, 2007 A.I.R. at para. 6 (India).
141. Novartis Case: Background and Update – Supreme Court of India to Recommence Hearing,
LAWYERS COLLECTIVE (Sept. 5, 2011), http://www.lawyerscollective.org/news/126-novartis-case-backgroundand-update-supreme-court-of-india-to-recommence-hearing.html.
142. Novartis AG, 2007 A.I.R. 24759 (India).
143. Id.; PB Jayakumar, Novartis Loses Battle for Cancer Drug Patent, BUS. STANDARD (July 5, 2009),
http://www.business-standard.com/india/storypage.php?autono=362951.
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144

The second issue involved examining whether Section 3(d) was
TRIPS.
145
consistent with Article 27 of TRIPS. The third issue was whether Section 3(d)
violated Article 14 of the Constitution of India because it was vague, arbitrary,
146
and conferred uncontrolled discretion to the Patent Controller.
The Court held that it did not have jurisdiction to adjudicate a case dealing
147
with the compliance of a domestic Indian law with an international treaty.
148
Since the Court
Thus, it did not grant any declaratory relief to Novartis.
decided that it did not have jurisdiction to adjudicate whether a domestic law
violated an international treaty, it declined to deal with the issue of whether
149
Section 3(d) was compliant with TRIPS. On the third issue, the Court held that
Section 3(d) did not violate Article 14 of the Indian Constitution, was not vague
150
or arbitrary, and did not confer uncontrolled discretion to the Patent Controller.
The Court concurred with the contention of the Indian Government that it had a
constitutional duty to provide good health care to its citizens by giving them easy
151
access to life-saving drugs. The Court also agreed that in doing so there should
be suitable legislative measures put in place to prevent evergreening of patents,
which could have disastrous consequences with respect to availability of
152
affordable medicines.
C. Inventive Step
Indian patent law now defines inventive step as “a feature of an invention
that involves technical advance as compared to the existing knowledge or having
economic significance or both and that makes the invention not obvious to a
153
person skilled in the art.” Thus, Indian law has tried to add new criteria like
“technical advance” and “economic significance” onto the standard nonobviousness requirement. Scholars opine that the new broadened definition of

144. Novartis AG, 2007 A.I.R. at para. 5(a) (India).
145. Id. at para. 5(b).
146. Id. at para. 5(c).
147. Id. at para. 7.
148. Id. at para. 9. According to the Court, a declaratory relief cannot be given where it would serve no
useful purpose to the petitioner. Moreover, a declaration that “the amended provision is not in discharge of
India’s obligation under Article 27 of ‘TRIPS” would not “compel the Parliament to enact a law,” thus the
petitioner would not receive any relief. Id.
149. Id. at para. 8.
150. Id. at para. 16.
151. Id. at para. 19.
152. Id. at para. 15. Patent evergreening refers to the strategy of obtaining multiple patents that deal
with different aspects of the same product, by obtaining patents on improved versions of existing products,
JOHN R. THOMAS, PATENT “EVERGREENING”: ISSUES IN INNOVATION AND COMPETITION (2009), available at
http://ipmall.info/hosted_resources/crs/R40917_091113.pdf.
153. The Patents (Amendment) Act, 2005, No. 15 sec. 2, Acts of Parliament, 2005 (India), available at
http://ipindia.nic.in/ipr/patent/patent_2005.pdf (which updates Section 2(ja)).
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inventive step will give “the Patent Office and courts an explicit mandate to
154
consider a claimed invention’s economic significance.”
D. Pre-Grant and Post-Grant Opposition Before the Patent Controller
Indian law provides two administrative opportunities to challenge the grant
155
of a patent before the patent offices: pre-grant and post-grant opposition. India
is one of the few systems to provide pre-grant as well as post-grant opposition
156
proceedings.
Interestingly, most advanced countries do not follow pre-grant
157
opposition proceedings.
India’s pre-grant procedure allows any person to file a pre-grant opposition
158
with the relevant patent office.
“Any person” has been interpreted to cover
potential generic competitors as well as social action groups representing
159
interests of patients suffering from various diseases like cancer and AIDS. The
160
grounds upon which a pre-grant opposition can be made are also very broad.
The grounds for opposition mainly consist of lack of novelty, lack of inventive
step, insufficiency of description, and non-patentability of the invention under the
161
existing law.
Though there is a considerable lack of information about the number of pregrant opposition proceedings filed before the Controller, there are some studies
162
that have put the figure at about 200 as of July 2007. The Patent Controller’s
163
website during the period 2005-11 gives information about eighty cases.
E. Compulsory Licensing Provisions
India’s law has very expansive compulsory licensing provisions.
Compulsory licensing may be invoked three years from the patent grant upon
satisfying the following conditions: (1) the “reasonable requirements of the
public with respect to the patented invention have not been satisfied;” (2) “the

154. Mueller, supra note 54, at 565.
155. The Patents (Amendment) Act, 2005, sec. 23 (which changed Section 25(1) and 25(2)).
156. Christopher Arup & Jagjit Plahe, Pharmaceutical Patent Networks: Assessing the Influence of
India’s Paragraph 3(d) Internationally, INTELL. PROP. Q. 1, 32 (2010).
157. See Jay P. Kesan, Carrots and Sticks to Create a Better Patent System, 17 BERKELEY TECH. L.J.
763, 781-82 (2002).
158. The Patents (Amendment) Act, 2005, sec. 25(1).
159. See Mueller, supra note 54, at 570-71. The Patents (Amendment) Act, 2005, Section 25(1) states
that opposition shall be made by way of representation to the Controller.
160. The Patents (Amendment) Act, 2005, sec. 25 (which updates 25(1)(a)-(k)).
161. Id.
162. Kapczynski, supra note 63, at 1599-1600.
163. Indian Patent Office, INTELL. PROP. INDIA (Mar. 2, 2012), http://ipindiaonline.gov.in/
patentsearch1/patentsearch.aspx. Although the website lists some 120 links, only 80 currently have files
attached.
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patented invention is not available to the public at a reasonable price;” and (3) the
164
patented invention is not worked in the territory of India.
Additionally, the Indian government may grant a compulsory license in
165
circumstances involving national health emergencies.
The law also provides
mechanisms to manufacture and export patented medicines to other countries
166
without local manufacturing capacity.
F. Government Use Provision
Indian law also provides for a mechanism allowing the government to use the
167
This is more or less in sync
patented invention under certain circumstances.
with TRIPS requirements, and the law provides adequate remuneration to the
patentee in each case—considering the economic value of the use of the patent—
and stipulates that the government notify patentees of the use as soon as
168
practicable, except in cases of emergency.
There is one more specific
provision, dealing with medicines, that allows the government to import patented
drugs or medicines “for the purpose merely of its own use or for distribution in
any dispensary, hospital or other medical institution maintained by or on behalf
169
of the Government” or designated under the Patents Act.
G. Experimental Use Exemptions
According to Indian law, any person may make or use the patented invention,
whether it is a product or a process—or even an article or product made by a
process—for the “purpose merely of experimentation or research including the
170
imparting of instructions to pupils.”
Scholars note that this provision seems more liberal than corresponding
provisions in most other countries, and that it is “wide enough to even support
activities such as ‘inventing around’ the patented invention or the making of
171
improvements thereto.”
Along with this general experimental use exception,
Indian law also exempts experimental trials conducted on patented drugs from

164. The Patents Act, No. 39 of 1970, INDIA CODE (1995) sec. 84(1)-(6), available at
http://indiacode.nic.in. The Patents Act also includes a list of instances where the reasonable requirements of
the public shall be deemed to be unsatisfied.
165. The Patents (Amendment) Act, 2005 sec. 55 (updating § 92A).
166. Id.
167. The Patents Act, No. 39 of 1970, INDIA CODE sec. 100(1) (1998).
168. The Patents (Amendment) Act, 2002, No. 38, Acts of Parliament, sec. 41, 2002 (India), available at
http://www.ipindia.nic.in/ipr/patent/patentg.pdf (updating Section 100(3)-(5)).
169. The Patents Act, No. 39 of 1970, sec. 47(4).
170. Id. at sec. 47(3).
171. Shamnad Basheer & Prashant Reddy, The “Experimental Use” Exception Through a
Developmental Lens, 50 INTELL. PROP. L. REV. 831, 832 (2010).
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172

This provision is much wider than the
the purview of patent infringement.
corresponding U.S. law, as it allows the “making, constructing, using or selling
of a ‘patented invention’ for the purpose of generating regulatory data to comply
with both domestic (Indian) drug regulatory law, and any corresponding foreign
law,” while U.S. law exempts only activities connected with a regulatory
173
submission within the United States.
H. Parallel Imports
India’s new Patents Act implements the principle of international
174
The expression “exhaustion of patent rights”
“exhaustion of patent rights.”
means that right holders who sell their invention lose the right to control the
175
resale of the invention. In other words, once a patented product has been sold
with the patentee’s approval outside India, the subsequent importation of that
same patented item into India will not amount to infringement of the Indian
176
patent. The law provides that “importation of patented products by any person
from a person who is duly authorised under the law to produce and sell or
distribute the product, shall not be considered as an infringement of patent
177
rights.”
While most developed countries’ patent regimes do not have provisions
incorporating international exhaustion of patent rights, the developing and least
developed countries have included them in their patent laws with the aim of
178
ensuring their citizens’ access to lower-cost medicines. The TRIPS Agreement
is also silent about international exhaustion, as Article 6 of the Agreement states
that “nothing in this Agreement shall be used to address the issue of the
179
exhaustion of intellectual property rights.”

172. The Patents (Amendment) Act, 2002, sec. 58 (which updates Section 107A).
173. Basheer & Reddy, supra note 171, at 871.
174. Enrico Bonadio, Parallel Imports in a Global Market: Should a Generalised International
Exhaustion Be the Next Step?, 33 EUR. INTELL. PROP. REV. 153, 153 (2011).
175. Id.
176. Id.
177. The Patents (Amendment) Act, 2002, sec. 44 (which updates §107A(b)); The Patents (Amendment)
Act, 2005, No. 15 sec. 58, Acts of Parliament, 2005 (India), available at http://ipindia.nic.in/ipr/patent/patent
_2005.pdf (which updates Section 107A(b)).
178. See Jacqui Wise, Access to AIDS Medicines Stumbles on Trade Rules, 84 BULL. WORLD HEALTH
ORG. 337 (2006), available at http://www.who.int/bulletin/volumes/84/5/news10506/en/index.html.
179. Agreement on Trade-Related Aspects of Intellectual Property Rights art. 6, Apr. 15, 1994,
Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, available at
http://www.wto.org/english/docs_e/legal_e/27-trips.pdf.
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VII. CONCLUSION
More than six years have passed since India implemented its new
180
pharmaceutical product patents regime. During this period, patent application
181
The jury is still out on the long-term
filings have increased dramatically.
implications of patent protection on drug pricing in India. However, this article
has demonstrated that the Indian government holds a number of tools to deal with
that concern.
It should also be noted that India’s generic drug makers, along with various
social action/public interest groups, have managed to put up a strong challenge to
182
multi-national companies holding pharmaceutical patents. Instead of taking the
situation lying down, they are proactively making full use of the available
183
statutory flexibilities to challenge pharmaceutical product patents.
The Indian Patent Office and courts face significant challenges in
interpreting and applying the new Patent Act’s provisions. While India’s patent
system emerges as a unique model, there will be greater demands from stakeholders to make the system more transparent. In the past two years, some
significant measures have been taken to increase transparency and it is expected
that more steps will follow. In the short-term, opponents of stronger patent
protection may be able to take advantage of ambiguities in the interpretation of
various provisions of the patent law. But this can have serious long-term
consequences, as a lack of confidence in the patent system could adversely
impact indigenous innovation to a large extent and foreign direct investment to a
small extent. Since India’s pharmaceutical industry today is completely different
184
than what it was in 1970, stronger IPRs may help them by supporting pathbreaking research and development. The entire world is looking at India to see
how its unique patent system is evolving, and only time will tell whether that
evolution takes the form of a smooth transition or a bumpy ride.

180. See History of Indian Patent System, supra note 13.
181. See 79,000 Patent Applications Are Pending at India Patent Office!, INDIAN INST. PAT. &
TRADEMARK ATT’Y (Aug. 6, 2010, 11:08 AM), http://www.iipta.com/ipr/79000-patent-applications-arepending-india-patent-office.
182. SUDIP CHAUDHURI, CHAN PARK & K.M. GOPAKUMAR, FIVE YEARS INTO THE PRODUCT PATENT
REGIME: INDIA’S RESPONSE 5 (2010).
183. There are numerous instances of Indian companies successfully opposing the patent applications of
foreign companies; one such case is Cipla’s pre-grant opposition of Novartis. See Novartis AG v. Union of
India, 2007 A.I.R. 24759 (Madras H.C.) (2007).
184. See History of Indian Patent System, supra note 13, at para. 3.

342

